ScholarIQanswers from OpenAlex & ORCID
Vera J. Suman
ResearcherPublications, citations & collaboration network
Vera J. Suman is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Vera J. Suman have?
ScholarIQindexed works
Vera J. Suman has 483 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Vera J. Suman have?
ScholarIQcitation count
Vera J. Suman has 30,420 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Vera J. Suman?
ScholarIQh-index
Vera J. Suman has an h-index of 78 in OpenAlex.
What is the i10-index of Vera J. Suman?
ScholarIQi10-index
Vera J. Suman has an i10-index of 239 in OpenAlex.
What is the ORCID of Vera J. Suman?
ScholarIQorcid
The ORCID for Vera J. Suman is on the source record.
What is the OpenAlex record for Vera J. Suman?
ScholarIQopenalex
The OpenAlex for Vera J. Suman is on the source record.
What are the most-cited papers on Vera J. Suman?
ScholarIQmost cited works
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer, Nancy E. Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela Klein, James N. Ingle, Norman Wolmark
Whole-genome analysis informs breast cancer response to aromatase inhibition
Matthew J. Ellis, Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, John W. Wallis, Brian Andrew Van Tine, Jeremy Hoog, Reece Goiffon, Theodore C. Goldstein, Sam Ng, Lin Li, Robert J. Crowder, Jacqueline Snider, Karla V. Ballman, Jason D. Weber, Ken Chen, Daniel C. Koboldt, Cyriac Kandoth, William Schierding, Joshua F. McMichael, Christopher A. Miller, Charles Lu, Christopher Harris, Michael D. McLellan, Michael C. Wendl, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie A. Margenthaler, Gildy V. Babiera, P. Kelly Marcom, J. Michael Guenther, Marilyn Leitch, Kelly K. Hunt, John A. Olson, Tao Yu, Christopher A. Maher, Lucinda Fulton, Robert S. Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L. Vickery, Adnan Elhammali, Helen Piwnica‐Worms, Sandra McDonald, Mark A. Watson, David J. Dooling, David M. Ota, Li-Wei Chang, Ron Bose, Timothy J. Ley, David Piwnica‐Worms, Joshua M. Stuart, Richard K. Wilson, Elaine R. Mardis
Benign Breast Disease and the Risk of Breast Cancer
Lynn C. Hartmann, Thomas A. Sellers, Marlene H. Frost, Wilma L. Lingle, Amy C. Degnim, Karthik Ghosh, Robert A. Vierkant, Shaun D. Maloney, V. Shane Pankratz, David W. Hillman, Vera J. Suman, Jo Johnson, Cassann Blake, Thea D. Tlsty, Celine M. Vachon, L. Joseph Melton, Daniel W. Visscher
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials
Edward L. Korn, Ping-Yu Liu, Sandra J. Lee, J. W. Chapman, Donna Niedzwiecki, Vera J. Suman, James Moon, Vernon K. Sondak, Michael B. Atkins, Elizabeth A. Eisenhauer, Wendy R. Parulekar, Svetomir N. Markovic, Scott Saxman, John M. Kirkwood
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
Matthew J. Ellis, Vera J. Suman, Jeremy Hoog, Lin Li, Jacqueline Snider, Aleix Prat, Joel S. Parker, Jingqin Luo, Katherine DeSchryver, D. Craig Allred, Laura J. Esserman, Gary Unzeitig, Julie Margenthaler, Gildy V. Babiera, P. Kelly Marcom, Joseph M. Guenther, Mark A. Watson, Marilyn Leitch, Kelly K. Hunt, John A. Olson